Last $7.02 USD
Change Today -0.35 / -4.75%
Volume 190.1K
As of 8:10 PM 09/19/14 All times are local (Market data is delayed by at least 15 minutes).

regulus therapeutics inc (RGLS) Snapshot

Previous Close
Day High
Day Low
52 Week High
02/25/14 - $11.88
52 Week Low
05/9/14 - $5.40
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

regulus therapeutics inc (RGLS) Related Businessweek News

View More BusinessWeek News

regulus therapeutics inc (RGLS) Details

Regulus Therapeutics Inc., a biopharmaceutical company, focuses on the discovery and development of drugs that target microRNAs for the treatment of various diseases in the United States. The company uses its microRNA product platform to develop anti-miRs, which is chemically modified and single-stranded oligonucleotide. Its clinical candidate products include RG-101, which is a GalNAc-conjugated anti-miR that targets microRNA-122 for the treatment of patients with chronic hepatitis C virus infection. The company has strategic collaboration with Biogen Idec MA Inc. for the evaluation of the use of microRNA signatures as a biomarker for human patients with multiple sclerosis; AstraZeneca AB to discover and develop microRNA therapeutics for cardiovascular diseases, metabolic diseases, and oncology; and GlaxoSmithKline plc to discover and develop microRNA therapeutics for immuno-inflammatory diseases. It also has strategic collaboration with Sanofi for the discovery and development of microRNA therapeutics comprising miR-21 pre-clinical fibrosis program for the treatment of alport syndrome and preclinical program for oncology indications; and preclinical programs targeting miR-221/222 for oncology indications. Regulus Therapeutics Inc. was founded in 2007 and is headquartered in San Diego, California.

81 Employees
Last Reported Date: 08/7/14
Founded in 2007

regulus therapeutics inc (RGLS) Top Compensated Officers

Chief Executive Officer, President, Principal...
Total Annual Compensation: $600.0K
Chief Scientific Officer
Total Annual Compensation: $350.0K
Compensation as of Fiscal Year 2013.

regulus therapeutics inc (RGLS) Key Developments

Regulus Therapeutics Inc. Initiates ATHENA Natural History of Disease Study in Alport Syndrome Patients

Regulus Therapeutics Inc. announced that it has initiated its ATHENA natural history of disease study in patients with Alport syndrome, a life-threatening genetic kidney disease with no approved therapy. The ATHENA study is designed to characterize the natural decline of renal function markers such as Glomerular Filtration Rate, creatinine, proteinuria and beta-2 microglobulin, in Alport syndrome patients over time. Over the course of two years, Regulus aims to enroll up to 120 Alport syndrome patients who are 16 years and older with a GFR between 30-75ml/min at planned clinical sites in the United States, Australia, Canada and Europe. The data collected from the ATHENA study will provide much needed information about the changes in renal function over time in Alport syndrome patients, which will inform future clinical development plans of Regulus' RG-012, a single stranded, chemically modified oligonucleotide that binds to and inhibits the function of microRNA-21, currently in development to treat renal dysfunction in Alport syndrome patients.

Regulus Therapeutics Inc. Announces Unaudited Earnings Results for the Second Quarter and Six Months Ended June 30, 2014; Provides Financial Guidance for the Year 2014

Regulus Therapeutics Inc. announced unaudited earnings results for the second quarter and six months ended June 30, 2014. For the quarter, the company reported total revenues of $736,000 against $4,759,000 a year ago. Loss from operations was $13,013,000 against $4,686,000 a year ago. Loss before income taxes was $11,973,000 against $7,338,000 a year ago. Net loss was $11,973,000 against $7,348,000 a year ago. Diluted net loss per share was $0.29 against $0.20 a year ago. Revenue during these periods consisted primarily of amortization of upfront payments received from strategic alliances and collaboration, which recognize over estimated period of performance. For the six months, the company reported total revenues of $2,367,000 against $7,997,000 a year ago. Loss from operations was $23,718,000 against $10,235,000 a year ago. Loss before income taxes was $24,713,000 against $14,576,000 a year ago. Net loss was $24,174,000 against $14,577,000 a year ago. Diluted net loss per share was $0.57 against $0.41 a year ago. The company expects to finish 2014 with at least $75 million in cash, cash equivalents and short-term investments.

Regulus Therapeutics Inc. to Report Q2, 2014 Results on Aug 06, 2014

Regulus Therapeutics Inc. announced that they will report Q2, 2014 results at 5:00 PM, Eastern Standard Time on Aug 06, 2014


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
RGLS:US $7.02 USD -0.35

RGLS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Benitec Biopharma Ltd A$1.03 AUD -0.005
Galena Biopharma Inc $2.19 USD 0.00
Prosensa Holding NV $8.66 USD -0.07
Silence Therapeutics PLC 212.00 GBp +6.00
Tekmira Pharmaceuticals Corp C$22.62 CAD -0.26
View Industry Companies

Industry Analysis


Industry Average

Valuation RGLS Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 22.9x
Price/Book 3.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales 14.6x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact REGULUS THERAPEUTICS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at